Androgens and bone metabolism

Joint Bone Spine

Volumn 72, Issue 3, 2005, Pages 202-206

  Alexandre, Christian ^a  

^a UNIVERSITÉ JEAN MONNET   (France)

Author keywords

Androgens; Estrogens; Men; Osteoporosis; Prostate cancer

Indexed keywords

ALENDRONIC ACID; ANDROGEN; ANTIANDROGEN; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ESTRONE; GONADORELIN AGONIST; PAMIDRONIC ACID; RALOXIFENE; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; STEROID HORMONE RECEPTOR BLOCKING AGENT; TESTOSTERONE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADULTHOOD; AGE DISTRIBUTION; ANDROGEN THERAPY; BONE ATROPHY; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE TURNOVER; CASTRATION; DRUG CONTRAINDICATION; ESTRADIOL BLOOD LEVEL; ESTROGEN ACTIVITY; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; ESTRONE BLOOD LEVEL; FEMINIZATION; FEMUR NECK FRACTURE; FRAGILITY FRACTURE; GENE INACTIVATION; HIGH RISK PATIENT; HORMONAL REGULATION; HORMONE ACTION; HORMONE RESISTANCE; HORMONE SYNTHESIS; HUMAN; HYPOGONADISM; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; PROSTATE CANCER; REIMBURSEMENT; REVIEW; RISK FACTOR; SIDE EFFECT; TESTIS FUNCTION; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

EID: 17844373819     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2004.04.004     Document Type: Short Survey

References (54)

1. Wahner H.W., Dunn W.L., Riggs B.L. Noninvasive bone mineral measurements. Semin Nucl Med. 13:1983;282-289
2. Kanis J.A., Melton L.J. III, Christiansen C., Johnston C.C., Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 9:1994;1137-1141
3. Mosekilde L., Mosekilde L. Sex differences in age-related changes in vertebral body size, density and biomechanical competence in normal individuals. Bone. 11:1990;67-73
4. Seeman E. Periosteal bone formation - a neglected determinant of bone strength. N Engl J Med. 349:2003;320-323
5. Center J.R., Nguyen T.V., Schneider D., Sambrook P.N., Eisman J.A. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 353:1999;878-882
6. Nguyen T.V., Eisman J.A., Kelly P.J., Sambrook P.N. Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol. 144:1996;255-263
7. Legrand E., Degasne I., Chappard D., Basle M.F., Audran M. Ostéoporoses. Encycl Med Chir (Elsevier Paris). 1999;. Appareil locomoteur, 14-027-G10, 15 p.
8. Bord S., Horner A., Beavan S., Compston J. Estrogen receptors alpha and beta are differentially expressed in developing human bone. J Clin Endocrinol Metab. 86:2001;2309-2314
9. Vanderschueren D., Bouillon R. Androgens and bone. Calcif Tissue Int. 56:1995;341-346
10. Kousteni S., Bellido T., Plotkin L.I., O'Brien C.A., Bodenner D.L., Han L., et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 104:2001;719-730
11. Finkelstein J.S., Klibanski A., Neer R.M., Greenspan S.L., Rosenthal D.I., Crowley W.F. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Int Med. 106:1987;354-361
12. Albright F., Bloomberg E., Smith P.H. Post-menopausal osteoporosis. Trans Assoc Am Phys. 55:1940;298-305
13. Behre H.M., Kliesch S., Leifke E., Link T.M., Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 82:1997;2386-2390
14. Lindsay R., Gallagher J.C., Kleerekoper M., Pickar J.H. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 287:2002;2668-2676
15. Smith E.P., Boyd J., Frank G.R., Takahashi H., Cohen R.A., Specker B., et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 331:1994;1056-1061
16. Morishima A., Grumbach M.M., Simpson E.R., Fisher C., Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 80:1995;3689-3698
17. Bilezikian J.P., Morishima A., Bell S., Grumbach M.M. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med. 339:1998;599-603
18. Carani C., Qin K., Simoni M., Faustini-Fustini M., Serpente S., Boyd J., et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med. 337:1997;91-95
19. Rochira V., Faustini-Fustini M., Balestrieri A., Carani C. Estrogen replacement therapy in a man with congenital aromatase deficiency: effects of different doses of transdermal estradiol on bone mineral density and hormonal parameters. J Clin Endocrinol Metab. 85:2000;1841-1845
20. Sims N.A., Clement-Lacroix P., Minet D., Fraslon-Vanhulle C., Gaillard-Kelly M., Resche-Rigon M., et al. A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol receptor-deficient mice. J Clin Invest. 111:2003;1319-1327
21. Marcus R., Leary D., Schneider D.L., Shane E., Favus M., Quigley C.A. The contribution of testosterone to skeletal development and maintenance: lessons from the androgen insensitivity syndrome. J Clin Endocrinol Metab. 85:2000;1032-1037
22. De Vernejoul M.C., Cohen Solal M. Estrogens, androgens, and osteoporosis in men. Ann Endocrinol (Paris). 64:2003;137-140
23. Khosla S., Melton L.J. III, Atkinson E.J., O'Fallon W.M., Klee G.G., Riggs B.L. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab. 83:1998;2266-2274
24. Greendale G.A., Edelstein S., Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res. 12:1997;1833-1843
25. Slemenda C.W., Longcope C., Zhou L., Hui S.L., Peacock M., Johnston C.C. Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest. 100:1997;1755-1759
26. Legrand E., Hedde C., Gallois Y., Degasne I., Boux de Casson F., Mathieu E., et al. Osteoporosis in men: a potential role for the sex hormone binding globulin. Bone. 29:2001;90-95
27. Khosla S., Melton L.J. III, Atkinson E.J., O'Fallon W.M. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab. 86:2001;3555-3561
28. Van Pottelbergh I., Goemaere S., Kaufman J.M. Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J Clin Endocrinol Metab. 88:2003;3075-3081
29. Khosla S., Melton L.J. III, Riggs B.L. Clinical review 144: estrogen and the male skeleton. J Clin Endocrinol Metab. 87:2002;1443-1450
30. Szulc P., Munoz F., Claustrat B., Garnero P., Marchand F., Duboeuf F., et al. Bio available estradiol may be an important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab. 86:2001;192-199
31. Falahati-Nini A., Riggs B.L., Atkinson E.J., O'Fallon W.M., Eastell R., Khosla S. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest. 106:2000;1553-1560
32. Leder B.Z., Le Blanc K.M., Schoenfeld D.A., Eastell R., Finkelstein J.S. Differential effects of androgens and estrogens on bone turn-over in hormonal men. J Clin Endocrinol Metab. 88:2003;204-210
33. Huggins C., Hodges C. Studies in prostate cancer. I. The effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1:1941;293-297
34. Seeman E. Pathogenesis of bone fragility in women and men. Lancet. 359:2002;1841-1850
35. Jackson J., Riggs M., Spiekerman A. Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. Am J Med Sci. 304:1992;4-8
36. Daniell H. Osteoporosis after orchiectomy for prostate cancer. J Urol. 157:1997;439-444
37. Dahmani L., Wagner B., Auzanneau C., Irani J., Dore B. Prevalence of osteoporotic fractures in patients treated by androgen blockade for prostate cancer. Prog Urol. 13:2003;73-78
38. Daniell H.W. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology. 58:(Suppl 1):2001;101-107
39. Melton L.J. III, Alothman K.I., Khosla S., Achenbach S.J., Oberg A.L., Zincke H. Fracture risk following bilateral orchiectomy. J Urol. 169:2003;1747-1750
40. Wei J.T., Gross M., Jaffe C.A., Gravlin K., Lahaie M., Faerber G.J., et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology. 54:1999;607-611
41. Preston D.M., Torrens J.I., Harding P., Howard R.S., Duncan W.E., McLeod D.G. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. Prostate Cancer Prostatic Dis. 5:2002;304-310
42. Kiratli B.J., Srinivas S., Perkash I., Terris M.K. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology. 57:2001;127-132
43. Smith M.R. Management of treatment-related osteoporosis in men with prostate cancer. Cancer Treat Rev. 29:2003;211-218
44. Smith M.R., McGovern F.J., Zietman A.L., Fallon M.A., Hayden D.L., Schoenfeld D.A., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 345:2001;948-955
45. Smith M.R., Eastham J., Gleason D.M., Shasha D., Tchekmedyian S., Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 169:2003;2008-2012
46. Diamond T.H., Winters J., Smith A., De Souza P., Kersley J.H., Lynch W.J., et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer. 92:2001;1444-1450
47. Vandenput L., Boonen S., Van Herck E., Swinnen J.V., Bouillon R., Vanderschueren D. Evidence from the aged orchidectomized male rat model that 17beta-estradiol is a more effective bone-sparing and anabolic agent than 5alpha-dihydrotestosterone. J Bone Miner Res. 17:2002;2080-2086
48. Vermeulen A. Androgen replacement therapy in the aging male - a critical evaluation. J Clin Endocrinol Metab. 86:2000;2380-2390
49. Gonnelli S., Cepollaro C., Montagnani A., Bruni D., Caffarelli C., Breschi M., et al. Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tissue Int. 73:2003;133-139
50. Hanada K., Furuya K., Yamamoto N., Nejishima H., Ichikawa K., Nakamura T., et al. Bone Anabolic Effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol Pharm Bull. 26:2003;1563-1569
51. Zacharin M.R., Pua J., Kanumakala S. Bone mineral density outcomes following long-term treatment with subcutaneous testosterone pellet implants in male hypogonadism. Clin Endocrinol (Oxf). 58:2003;691-695
52. Ongphiphadhanakul B., Thamprajamchit S., Chanprasertyothin S., Chailurkit L., Rajatanavin R. Effect of estrogen replacement on insulin sensitivity, serum lipid and bone resorption marker in hypogonadal males. Maturitas. 42:2002;85-89
53. Doran P.M., Riggs B.L., Atkinson E.J., Khosla S. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res. 16:2001;2118-2125
54. Kim I.Y., Seong do H., Kim B.C., Lee D.K., Remaley A.T., Leach F., et al. Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway. Cancer Res. 62:2002;3649-3653